Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure

Soluble ST2 (sST2) is a novel biomarker implicated in myocardial remodelling and fibrosis. Recent studies in normal subjects have suggested the biological variability (BV) of sST2 is significantly lower than that of the Btype natriuretic peptides, BNP & NTproBNP. It may, consequently, be a better biomarker for monitoring patients with chronic heart failure (CHF). To date, no published studies have examined the BV of sST2 in a heart failure population.Blood samples from 50 outpatients with pharmacologically optimised stable CHF and persistent left ventricular dysfunction (ejection fraction (EF) <40%).were collected at baseline, 1 hour, 1 month, 3 months and 6 months. Using log-transformed data, mean intra-individual coefficients of variation (CV I ) and

show abstract

“…A subset of this cohort has been previously described 10 . All were on optimum tolerated heart failure medications.…”

Section: Methodsmentioning

confidence: 99%

Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring

Piper

DeCourcey

Sherwood

et al. 2016

The American Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…sST2 levels have been also identified as a biomarker in heart failure, efficiently assessing cardiac remodelling and fibrosis; sST2 has been shown to efficiently monitor the effectiveness of an optimized treatment in chronic heart failure patients [44], with increased levels that may be a good predictor of cardiac decompensation as well as worsening renal function.…”

Section: Discussionmentioning

confidence: 99%

Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution

et al. 2016

View full text Add to dashboard Cite

BackgroundThe ST2/IL-33 pathway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to disease severity. We tested the potential usefulness of sST2 as a predictive marker of treatment response and patients’ outcome.MethodsTwenty-six patients with active UC were prospectively recruited and grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and 6 months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, 1, 3, 6 and 12 months. Serum and mucosal ST2, and fecal calprotectin (FC) content were determined by ELISA and correlated to Mayo clinical and endoscopic subscore. Intestinal ST2 was evaluated by immunofluorescence. Wilcoxon signed rank test and Spearman correlations (Rs) were applied (p <0.05).ResultsFollow-up was completed in 24 patients. sST2 levels (median and range) varied from 173.5 [136.6–274.0] to 86.5 [54.6–133.2] in responders (p < 0.05), and 336.3 [211.0–403.2] to 385.3 pg/mL [283.4–517.3] in non-responders at baseline and 6 months, respectively. sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and FC (Rs = 0.57, 0.66, 0.74 and 0.42, respectively; p < 0.0001) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.ConclusionsConsecutive sST2 measurement to follow changes in inflammatory activity of UC patients who respond or not to treatment identifies sST2, like FC, as a useful biomarker in predicting clinical outcome of UC patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s12876-016-0520-6) contains supplementary material, which is available to authorized users.

show abstract

“…Кроме того, уровень изменения биомаркеров между исходным зна-чением и по истечении 6 мес. достоверно отличался по концентрации ST-2 (AUC =0,738; 95% ДИ 0,584-0,971) и не имел достоверных различий по уровню NTproBNP (AUC =0,425; 95% ДИ 0,211-0,638; p=0,501) [39]. Роль серийной оценки ST-2 для улучшения риск-стратификации и влияния терапии изучалась и в отдель-ных оригинальных исследованиях [40].…”

Section: таблица 2 пороговые значения натрий-уретических пептидов дляunclassified

Molecular Biomarkers for Diagnostics, Risk Stratification and Prediction of Chronic Heart Failure

Медведева¹,

Суркова²,

Лимарева³

et al. 2016

Russ J Cardiol

View full text Add to dashboard Cite

Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure

Cited by 27 publications

References 49 publications

Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring

Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring

Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution

Molecular Biomarkers for Diagnostics, Risk Stratification and Prediction of Chronic Heart Failure

Contact Info

Product

Resources

About